entertainment -WSS

entertainment

author：focus 2025-08-28 13:05:52 - browse：96

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Bristol Myers buys into radiopharmaceuticals with RayzeBio

explore

WSS

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Three trends to watch in biotech in 2024

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Violet CEO on training clinicians to promote more inclusive care

After half a century, Israel moves to evict squatter from his cave home on the beach

Britney Spears to release memoir, 'The Woman In Me,' later this year

hotspot

entertainment

focus

Bright Health sells Medicare Advantage business to Molina

Digital health funding stays low as a new reality sets in

In Memoriam: Notable people who died in 2023

In Spain, a hospital brews its own CAR

Hollywood unions extend contract negotiations for actors

Readout Newsletter: The latest on Moderna, Apellis, and Merck

ChatGPT in medicine: STAT answers readers' burning questions

Grail spinoff by Illumina should end disastrous merger attempt

Drug repurposing or repositioning? The language matters

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

focus

A Greenpeace activist is fined for crash

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

SEC charges former device maker CEO with $41 million fraud

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Prime Medicine, Myeloid Therapeutics clash over genome

Wikipedia

explore

entertainment

hotspot